Jason Grebely
www.kirby.unsw.edu.au
0000-0002-1833-2017
20 papers found
Refreshing results…
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta‐analysis
Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: Findings from a cross‐sectional study in three Australian cities
Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence
Frequency of injecting among people who inject drugs: A systematic review and meta-analysis
The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis
An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study
Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study
Modelling the potential prevention benefits of a treat‐all hepatitis C treatment strategy at global, regional and country levels: A modelling study
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies
Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?
Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing anAddictionseries
Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing
Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study
Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs
Missing publications? Search for publications with a matching author name.